Oct 31, 2023 / 12:00PM GMT
Operator
Good day, everyone and welcome to the Neurocrine Biosciences Reports Third Quarter results. (Operator Instructions) Please note this call is being recorded. (Operator Instructions).
It is now my pleasure to turn the conference over to Todd Tushla, President of Investor Relations. Please go ahead.
Todd Tushla -
Good morning. Happy Halloween and thanks for joining Neurocrine's Third Quarter 2023 Earnings Call. I'm pleased to be joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we're going to try and get to all of your questions. So Kevin, take it away.
Kevin C.
Q3 2023 Neurocrine Biosciences Inc Earnings Call Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers